Prestige Consumer Healthcare has recalled approximately 40,000 bottles of Clear Eyes Maximum Itchy Eye Relief drops due to potential sterility contamination, the FDA announced. The voluntary recall targets batches that lack proper assurance of sterile conditions during manufacturing, presenting a health risk to consumers who use the eye drops.
The contamination concern centers on microbiological safety. Eye drops require strict sterilization protocols because any bacterial or fungal contamination introduced directly into the eye can cause serious infections, including conjunctivitis, keratitis, or other ocular complications. The FDA classified this recall as a potential public health hazard warranting immediate action.
Prestige Consumer Healthcare, which owns the Clear Eyes brand portfolio, initiated the recall proactively after identifying the sterility assurance gap in specific product batches. The company manufactures Clear Eyes through various formulations targeting different eye conditions. Maximum Itchy Eye Relief represents one of the brand's over-the-counter offerings targeting allergy-related eye itching and irritation.
The recall affects specific lot numbers distributed across the United States. Consumers holding affected bottles should stop use immediately and either discard the product or return it to the retailer where purchased. Prestige Consumer Healthcare established a customer service line to address consumer inquiries and facilitate returns or refunds.
This recall underscores ongoing quality control challenges in the over-the-counter pharmaceutical and consumer health sector. Eye drop recalls have occurred periodically over recent years, with some linked to serious contamination events. In 2023, the FDA investigated outbreaks of eye infections linked to contaminated artificial tears, highlighting how sterile manufacturing failures in this category carry tangible health consequences.
Prestige Consumer Healthcare trades as PBH on the New York Stock Exchange. The company generates revenue across multiple consumer health segments including eye care, digestive health, and dermatological products. Clear Eyes represents one of its marquee brands in the competitive over-the-counter eye care category, competing against products from Johnson & Johnson and other major consumer health manufacturers.
The financial impact on Prestige Consumer Healthcare depends on recall scope and duration. A 40,000-unit recall represents a modest volume relative to annual Clear Eyes sales, though reputational damage and litigation risk warrant monitoring. The company's stock performance reflects broader dynamics in the consumer health space, where margin pressures and regulatory scrutiny affect valuations.
Retailers carrying Clear Eyes Maximum Itchy Eye Relief should verify inventory against the affected lot numbers and remove contaminated stock from shelves. Pharmacies and drugstores maintain primary responsibility for customer communication regarding product safety issues.
The FDA will continue monitoring this situation and expects Prestige Consumer Healthcare to implement corrective manufacturing measures before resuming production of affected batches. Any additional information regarding adverse events or further contamination discoveries would trigger expanded recall protocols.
Consumers experiencing eye irritation, redness, or discharge after using affected Clear Eyes batches should consult healthcare providers immediately. Early detection of microbial contamination prevents serious infection progression.